Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical outcomes of relapsed refractory acute myeloid luekemia patients treated with venetoclax combination therapy and to analyze molecular predictors of these outcomes

Next Previous
X
Search
Trial Profile

Clinical outcomes of relapsed refractory acute myeloid luekemia patients treated with venetoclax combination therapy and to analyze molecular predictors of these outcomes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Jan 2021 New trial record
    • 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top